NEW YORK (Reuters Health) - Weeks before a damaging report on the diabetes drug Avandia (rosiglitazone) was to appear in The New England Journal of Medicine, a peer reviewer for the journal broke confidentiality rules by sending a copy of the results to an employee of the drug's manufacturer, a report released Wednesday in Nature indicates.